Preparation and Administration

KINERET preparation and administration

What to consider when prescribing KINERET

Here you’ll find helpful information about dosing, administration, expectations, and other things to note as you start your patient on KINERET.

A grandmother (the patient named Peggy) and grandfather play with their grandkids outside on the grass

Storage and handling

KINERET comes in a 100-mg syringe1

  • Syringes are prefilled, graduated glass
  • Single use
  • Available in a 7-day pack

How to store KINERET1

An illustrated icon of a snowflake and a thermometer

Keep in a refrigerator between 36°F and 46°F (2°C-8°C)

An illustrated icon of a refrigerator with a snowflake on it

Do not freeze or shake

An illustrated icon of the sun with a diagonal line going through it

Keep KINERET in its original carton and away from light

For RA: dosing and administration

How to inject KINERET for adults

This video offers simple, step-by-step instructions on how to store and inject KINERET. Be sure to share this video or the printable treatment guide with your patient.

Because of its short half-life, KINERET must be injected daily. RA patients should receive a 100-mg injection around the same time each day.1

Setting expectations

KINERET may take a few months to start working. Most RA patients who experience improvement see results within 3 months, though some patients continue to improve up to 6 months after starting treatment. It’s important to encourage your patient to continue their treatment plan to see if KINERET is right for them.1

How to inject a child with KINERET

This video offers simple, step-by-step instructions on how to store KINERET and give a child their daily dose. Be sure to share this video or the printable treatment guide with your patient and their family.

Your patient may experience injection site reactions

Injection site reactions (ISRs) are common side effects of KINERET. Most ISRs are mild, and usually stop about 14 to 28 days after starting treatment. Be sure to share tips on managing ISRs from our printable treatment guide with any patient who has been prescribed KINERET.1

Download patient resources
PREVIOUS:   DIRA Safety
NEXT:   Dosing Calculator
Indications and Important Safety Information
INDICATION

KINERET® (anakinra) is an interleukin-1 receptor antagonist indicated for:

Rheumatoid Arthritis (RA). Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease-modifying antirheumatic drugs (DMARDs)

Cryopyrin-Associated Periodic Syndromes (CAPS). Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID)

Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

CONTRAINDICATION

KINERET is contraindicated in patients with known hypersensitivity to E. coli–derived proteins, KINERET, or to any components of the product

IMPORTANT SAFETY INFORMATION

Serious Infections. In RA, discontinue use if serious infection develops. In KINERET-treated NOMID or DIRA patients, the risk of a disease flare when discontinuing KINERET treatment should be weighed against the potential risk of continued treatment. Do not initiate KINERET in patients with active infections

Use in combination with Tumor Necrosis Factor (TNF)-blocking agents is not recommended

Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported. Patients with DIRA may have an increased risk of allergic reactions, particularly in the first several weeks after starting KINERET treatment

Immunosuppression. The impact of treatment with KINERET on active and/or chronic infections and the development of malignancies is not known

Immunizations. Live vaccines should not be given concurrently with KINERET

Neutrophil counts should be assessed prior to initiating KINERET treatment, and while receiving KINERET, monthly for 3 months, and thereafter quarterly for a period up to 1 year

Serious Adverse Reactions

RA: The most serious adverse reactions were: Serious Infections and Neutropenia, particularly when used in combination with TNF blocking agents.

NOMID and DIRA: The most serious adverse events were infections.

Most Common Adverse Reactions

RA: The most common adverse reactions (incidence ≥ 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu-like symptoms, and abdominal pain

NOMID: The most common AEs during the first 6 months of treatment (incidence > 10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis

DIRA: The most common AEs are upper respiratory tract infections, rash, pyrexia, influenza-like illness, and gastroenteritis

Post-marketing Experience

Hepato-biliary disorders (elevations of transaminases; non-infectious hepatitis) and thrombocytopenia, including severe thrombocytopenia have been identified during postapproval use of KINERET. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

These are not all the possible risks associated with KINERET. Please see Full Prescribing Information for KINERET at https://www.kineretrx.com/hcp/
To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088
Click here for full Prescribing Information for KINERET.

Reference: 1. KINERET [Prescribing Information]. Stockholm, Sweden: Swedish Orphan Biovitrum AB (publ).